KP1077 Is Safe, Tolerable for Improving Idiopathic Hypersomnia Symptoms

A phase 2 trial found KP1077 provides clinically meaningful benefits for idiopathic hypersomnia.

Related Keywords

United States ,American ,Christopher Drake ,Henry Ford Health Christopher Drake ,American Academy Of Sleep Medicine ,Drug Administration ,Us Drug Enforcement Agency ,Henry Ford Health ,Zevra Therapeutics ,American Academy ,Orphan Drug Designation ,Enforcement Agency ,Epworth Sleepiness Scale ,Idiopathic Hypersomnia Severity Scale ,Sleep Inertia Visual Analog Scale ,Epworth Sleepiness ,Brain Fog Severity Scale ,Therapeutics Announces Top Line Data ,Global News ,Kind Indication ,Chronic Sleep Disorder ,Accessed March ,Idiopathic Hypersomnia ,Sleep ,Sleep Problems ,Excessive Sleepiness ,Kp1077 ,Serdexmethylphenidate ,